Bacopaside X
(Synonyms: 假马齿苋皂苷VII,Bacopaside VII) 目录号 : GC45938
A triterpenoid saponin
Cas No.:94443-88-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Bacopaside X is a triterpenoid saponin that has been found in B. monniera and has antifungal and anticancer activities.1,2,3 It inhibits the growth of the fungi C. albicans, C. neoformans, and A. fumigatus (MIC = 50 μg/ml for all).2 Bacopaside X decreases the proliferation of MDA-MB-231, SHG44, HCT8, A549, and PC3M cancer cell lines with IC50 values of 14.3, 15.9, 9.8, 9.7, and 10.1 μM, respectively.3 It reduces tumor growth by 84.13% in an S180 sarcoma mouse allograft model when administered at a dose of 50 μmol/kg.
|1. Zhou, Y., Shen, Y.-H., Zhang, C., et al. Triterpene saponins from Bacopa monnieri and their antidepressant effects in two mice models. J. Nat. Prod. 70(4), 652-655 (2007).|2. Li, X.-C., ElSohly, H.N., Nimrod, A.C., et al. Antifungal jujubogenin saponins from Colubrina retusa. J. Nat. Prod. 62(5), 674-677 (1999).|3. Peng, L., Zhou, Y., Kong, D.Y., et al. Antitumor activities of dammarane triterpene saponins from Bacopa monniera. Phytother. Res. 24(6), 864-868 (2010).
| Cas No. | 94443-88-6 | SDF | |
| 别名 | 假马齿苋皂苷VII,Bacopaside VII | ||
| Canonical SMILES | C[C@]([C@]1([H])CC2)(CC[C@]3([H])[C@@]1(CC[C@H](O[C@@](OC[C@H](O)[C@@H]4O[C@]([C@@H]([C@@H](O)[C@@H]5O)O)([H])O[C@@H]5CO)([H])[C@@H]4O[C@]6([H])O[C@@H](CO)[C@H](O)[C@H]6O)C3(C)C)C)[C@@]7(CO8)[C@@]2([H])[C@]([C@@](C)(O)C[C@H](/C=C(C)/C)O9)([H])[C@@]89 | ||
| 分子式 | C46H74O17 | 分子量 | 899.1 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1122 mL | 5.5611 mL | 11.1222 mL |
| 5 mM | 0.2224 mL | 1.1122 mL | 2.2244 mL |
| 10 mM | 0.1112 mL | 0.5561 mL | 1.1122 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Curr Neuropharmacol 2019;17(5):438-446.PMID:29676230DOI:10.2174/1570159X16666180419123022.
Bacopa monnieri, commonly known as Brahmi, has been extensively used as a neuromedicine for various disorders such as anxiety, depression and memory loss. Chemical characterization studies revealed the major active constituents of the herb as the triterpenoid saponins, bacosides. Bacoside A, the vital neuroprotective constituent, is composed of four constituents viz., bacoside A3, bacopaside II, jujubogenin isomer of bacopasaponin C (Bacopaside X) and bacopasaponin C. B. monnieri extracts as well as bacosides successfully establish a healthy antioxidant environment in various tissues especially in the liver and brain. Free radical scavenging, suppression of lipid peroxidation and activation of antioxidant enzymes by bacosides help to attain a physiological state of minimized oxidative stress. The molecular basis of neuroprotective activity of bacosides is attributed to the regulation of mRNA translation and surface expression of neuroreceptors such as AMPAR, NMDAR and GABAR in the various parts of the brain. Bioavailability as well as binding of neuroprotective agents (such as bacosides) to these receptors is controlled by the Blood Brain Barrier (BBB). However, nano conversion of these drug candidates easily resolves the BBB restriction and carries a promising role in future therapies. This review summarizes the neuroprotective functions of B. monnieri extracts as well as its active compounds (bacoside A, bacopaside I) and the molecular mechanisms responsible for these pharmacological activities.
Estimation of twelve bacopa saponins in Bacopa monnieri extracts and formulations by high-performance liquid chromatography
Chem Pharm Bull (Tokyo) 2006 Jun;54(6):907-11.PMID:16755069DOI:10.1248/cpb.54.907.
A simple and sensitive reversed phase high performance liquid chromatographic (HPLC) method has been developed for the simultaneous determination of twelve bacopa saponins present in the extracts of the Indian Medicinal Plant, Bacopa monnieri. The separation was achieved on a reversed phase C(18) column (Luna C(18)), 5 microm by isocratic elution with 0.05 M sodium sulphate buffer (pH 2.3) and acetonitrile (68.5 : 31.5, v/v) as the mobile phase at a flow rate of 1.0 ml/min with an operating temperature of 30 degrees C. The method was validated for linearity, precision, intra- and inter-day precision and accuracy. Several Bacopa samples (plant materials, extracts and commercial formulations) were successfully analyzed. Major bacopasaponins were bacosides A(3) (3), bacopaside II (4), bacopaside I (5), Bacopaside X (6), bacopasaponin C (7), bacopaside N2 (9) and the minor components were bacopasaponin F (1), bacopasaponin E (2), bacopaside N1 (8) bacopaside III (10), bacopaside IV (11) and bacopaside V (12). The total saponin content in the samples, plant materials and extracts varied from 5.1 to 22.17% and 1.47 to 66.03 mg/capsule or tablet in the commercial formulations.
Enhanced production of Bacopa saponins by repeated batch strategy in bioreactor
Bioprocess Biosyst Eng 2022 May;45(5):829-841.PMID:35119526DOI:10.1007/s00449-022-02700-4.
Cultivation of cell suspension culture of Bacopa monnieri targeting the production of bacosides was explored in a 5-l stirred tank reactor using statistically optimized conditions. The bioreactor cultivation conditions were modified and this led to profuse biomass growth (2.81 ± 0.20 g/l) and total bacosides (1.26 ± 0.23 mg/g in cells and 0.60 ± 0.11 mg/l in fermenter broth) production in 9 days. The values of static volumetric mass transfer coefficient (kLa), dimensionless mixing time (Nm) were measured in the bioreactor. The culture grew efficiently and produced enhanced amount of bacoside A (5.59 ± 0.41 mg/g total bacosides in cells and 3.12 ± 0.13 mg/l in the fermenter broth) using one cycle of repeated batch strategy adopted in the bioreactor for 15 days. The intracellular concentration of bacoside A3 (1.18 ± 0.11 mg/g), bacopaside II (2.09 ± 0.35 mg/g), Bacopaside X (0.79 ± 0.17 mg/g) and bacopasaponin C (2.24 ± 0.23 mg/g) were significantly higher in repeated batch as compared to batch bioreactor cultivation. The yield of total bacosides in the fermenter broth was 5-times higher in repeated batch as compared to batch cultivation. This strategy can be helpful for the enhanced production of other valuable triterpenoid saponins.
Micropropagation and elicited production of triterpenoid saponin glycosides and stigmasterol via precursor and elicitor feeding in Bacopa floribunda (R.Br.) Wettst.-A potential nootropic herb
Front Plant Sci 2023 Jan 31;14:1096842.PMID:36798714DOI:10.3389/fpls.2023.1096842.
Bacopa floribunda (Family: Plantaginaceae) is used in folklore medicines for the management of cognitive dysfunction. It has nootropic, antiaging, anti-inflammatory, anti-cholinesterase, and antioxidant properties. We developed an efficient and reproducible protocol for in vitro propagation of B. floribunda using the nodal explants. We assessed the effects of Murashige and Skoog (MS) medium fortified with various plant growth regulatory substances (PGRs), a precursor, and elicitors and their optimal combinations on regeneration and production of total saponins, triterpenoid saponin glycosides (bacoside A3, Bacopaside X, bacopaside II, and bacosaponin C), and stigmasterol content in in vitro grown biomass of B. floribunda. The growth of the shoots and roots was stimulated by MS + 2.0 mg/l BAP + 2.0 mg/l KIN and MS + 0.5 mg/l IAA + 0.5 mg/l IBA + 1.0 mg/l NAA, respectively. After 10 weeks of acclimatization, plantlets of B. floribunda had a survival rate of 95%. The highest total saponin content (35.95 ± 0.022 mg DE/g DW) was noted in the treatment of MS + 2.0 mg/l BAP + 1.5 μM SQ. Similarly, total triterpenoid saponin glycosides and stigmasterol were found maximum in biomass derived from MS + 2.0 mg/l BAP + 1.5 μM SQ and MS + 2.0 mg/l BAP, respectively. At the same treatments, bacoside A3 (1.01 ± 0.195 mg/g DW), bacopaside II (43.62 ± 0.657 mg/g DW), Bacopaside X (1.23 ± 0.570 mg/g DW), bacosaponin C (0.19 ± 0.195 mg/g DW), and stigmasterol (7.69 ± 0.102 mg/g DW) were reported. The present findings will help to highlight B. floribunda as a potent memory-enhancing herb, and in future also, it could be a potential substitute to B. monnieri. The current work is the first to describe the micropropagation and the elicited production of bioactive metabolites from the in vitro grown biomass of B. floribunda. In addition, further research is needed on production of bioactives, their pharmacological effects, and the elicited production using callus, cell suspension, and hairy root cultures.
Silica-based monolithic column with evaporative light scattering detector for HPLC analysis of bacosides and apigenin in Bacopa monnieri
J Sep Sci 2009 Aug;32(15-16):2812-8.PMID:19606439DOI:10.1002/jssc.200900082.
A high performance liquid chromatographic method using a silica-based monolithic column coupled with evaporative light scattering detector (HPLC-ELSD) was developed and validated for simultaneous quantification of bacosides (bacoside A, bacopaside I, bacoside A(3), bacopaside II, Bacopaside X, bacopasaponin C) and apigenin in Bacopa monnieri. The chromatographic resolution was achieved on a Chromolith RP-18 (100x4.6 mm) column with acetonitrile/water (30:70) as mobile phase in isocratic elution at a flow rate of 0.7 mL/min. The drift tube temperature of the ELSD was set to 95 degrees C, and the nitrogen flow rate was 2.0 SLM (standard liter per minute). The calibration curves revealed a good linear relationship (r(2) > 0.9988) within the test ranges. The detection limits (S/N = 3) and the quantification limits (S/N = 10) for the compounds were in the range of 0.54-6.06 and 1.61-18.78 microg/mL, respectively. Satisfactory average recovery was observed in the range of 95.8-99.0%. The method showed good reproducibility for the quantification of these compounds in B. monnieri with intra- and inter-day precision of less than 0.69 and 0.67%, respectively. The validated method was successfully applied to quantify analytes in nine accessions of B. monnieri and thus provides a new basis for overall quality assessment of B. monnieri.